Yousif Capital Management LLC Purchases Shares of 7,078 Smith & Nephew SNATS, Inc. $SNN

Yousif Capital Management LLC acquired a new position in shares of Smith & Nephew SNATS, Inc. (NYSE:SNN) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 7,078 shares of the medical equipment provider’s stock, valued at approximately $217,000.

Several other institutional investors have also made changes to their positions in the business. Scharf Investments LLC increased its stake in Smith & Nephew SNATS by 0.3% in the second quarter. Scharf Investments LLC now owns 2,083,513 shares of the medical equipment provider’s stock valued at $63,818,000 after acquiring an additional 6,993 shares during the period. Goldman Sachs Group Inc. lifted its stake in Smith & Nephew SNATS by 49.2% during the first quarter. Goldman Sachs Group Inc. now owns 1,771,401 shares of the medical equipment provider’s stock worth $50,255,000 after purchasing an additional 583,809 shares during the period. Armistice Capital LLC boosted its holdings in Smith & Nephew SNATS by 258.1% during the first quarter. Armistice Capital LLC now owns 1,769,000 shares of the medical equipment provider’s stock valued at $50,187,000 after purchasing an additional 1,275,000 shares in the last quarter. Clark Estates Inc. NY grew its stake in shares of Smith & Nephew SNATS by 6.3% in the 1st quarter. Clark Estates Inc. NY now owns 850,000 shares of the medical equipment provider’s stock valued at $24,114,000 after purchasing an additional 50,000 shares during the period. Finally, Northern Trust Corp grew its stake in shares of Smith & Nephew SNATS by 32.7% in the 1st quarter. Northern Trust Corp now owns 674,640 shares of the medical equipment provider’s stock valued at $19,140,000 after purchasing an additional 166,248 shares during the period. 25.64% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several analysts recently commented on the company. Royal Bank Of Canada reaffirmed an “outperform” rating on shares of Smith & Nephew SNATS in a research note on Monday. Weiss Ratings reissued a “hold (c+)” rating on shares of Smith & Nephew SNATS in a report on Friday. Canaccord Genuity Group boosted their target price on shares of Smith & Nephew SNATS from $28.00 to $36.00 and gave the company a “hold” rating in a research note on Monday, August 18th. Wall Street Zen lowered shares of Smith & Nephew SNATS from a “strong-buy” rating to a “buy” rating in a report on Friday, October 3rd. Finally, Sanford C. Bernstein set a $37.50 price target on shares of Smith & Nephew SNATS and gave the company a “market perform” rating in a report on Tuesday, October 14th. One equities research analyst has rated the stock with a Buy rating and eight have assigned a Hold rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $36.75.

Smith & Nephew SNATS Trading Up 0.3%

SNN opened at $36.59 on Friday. Smith & Nephew SNATS, Inc. has a 1-year low of $23.69 and a 1-year high of $38.79. The stock has a market capitalization of $15.62 billion, a PE ratio of 16.94, a PEG ratio of 0.99 and a beta of 0.69. The company has a current ratio of 3.00, a quick ratio of 1.40 and a debt-to-equity ratio of 0.60. The firm has a 50-day moving average price of $36.73 and a two-hundred day moving average price of $32.05.

Smith & Nephew SNATS Cuts Dividend

The business also recently disclosed a semi-annual dividend, which will be paid on Friday, November 7th. Investors of record on Friday, October 3rd will be given a $0.285 dividend. This represents a yield of 165.0%. The ex-dividend date is Friday, October 3rd. Smith & Nephew SNATS’s payout ratio is 26.39%.

Smith & Nephew SNATS Company Profile

Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT.